Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
|Videos|August 19, 2022
Advice from a Raindrop
Author(s)Richard M. Berlin, MD
"You think you’re too small to make a difference?"
Advertisement
Any Good Poem
Richard Berlin, MD, shares the poem "
Dr Berlin has been writing a poem about his experience of being a doctor every month for the past 24 years in Psychiatric Times™ in a column called “Poetry of the Times.” He is instructor in psychiatry, University of Massachusetts Medical School, Worcester, Massachusetts. His latest book is
Advertisement
Related to this article
A psychiatric NP shares mentorship lessons, training fixes, and her Psych NP Boot Camp—plus practical tips to close prescriber gaps and improve team-based care.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
How past “untreatable” labels mislead psychiatry—and why measurement-informed care and difficult-to-treat depression replace today’s treatment-resistant mindset.
There is a question older than medicine, and perhaps older than philosophy, that psychiatry has largely avoided: What makes us human?
Advertisement
Advertisement
Trending on Psychiatric Times
1
The First Ever Treatment-Resistant Depression Awareness Day
2
Reframing “Treatment-Resistant” as “Difficult-To-Treat”
3
How Best to Manage Treatment-Resistant Depression
4
Formulations Matter: The Approval of Olanzapine Extended-Release Injectable Suspension for Schizophrenia
5